MX9200755A - Tratamiento de carcinoma pulmonar de celulas no pequeñas. - Google Patents
Tratamiento de carcinoma pulmonar de celulas no pequeñas.Info
- Publication number
- MX9200755A MX9200755A MX9200755A MX9200755A MX9200755A MX 9200755 A MX9200755 A MX 9200755A MX 9200755 A MX9200755 A MX 9200755A MX 9200755 A MX9200755 A MX 9200755A MX 9200755 A MX9200755 A MX 9200755A
- Authority
- MX
- Mexico
- Prior art keywords
- small cell
- cell lung
- lung carcinoma
- treatment
- human
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65893791A | 1991-02-21 | 1991-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9200755A true MX9200755A (es) | 1992-08-01 |
Family
ID=24643331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9200755A MX9200755A (es) | 1991-02-21 | 1992-02-21 | Tratamiento de carcinoma pulmonar de celulas no pequeñas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5756512A (es) |
| EP (1) | EP0572549B1 (es) |
| JP (1) | JP2738979B2 (es) |
| KR (1) | KR930702984A (es) |
| AT (1) | ATE227991T1 (es) |
| AU (2) | AU1531992A (es) |
| CA (1) | CA2103707C (es) |
| DE (1) | DE69232852T2 (es) |
| DK (1) | DK0572549T3 (es) |
| ES (1) | ES2187500T3 (es) |
| HK (1) | HK1012267A1 (es) |
| MX (1) | MX9200755A (es) |
| PT (1) | PT100155B (es) |
| WO (1) | WO1992014471A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7732996A (en) * | 1995-11-22 | 1997-06-11 | Research Triangle Institute | Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties |
| US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
-
1992
- 1992-02-07 EP EP92907467A patent/EP0572549B1/en not_active Expired - Lifetime
- 1992-02-07 WO PCT/US1992/001034 patent/WO1992014471A1/en active IP Right Grant
- 1992-02-07 KR KR1019930702491A patent/KR930702984A/ko not_active Application Discontinuation
- 1992-02-07 CA CA002103707A patent/CA2103707C/en not_active Expired - Fee Related
- 1992-02-07 JP JP4507270A patent/JP2738979B2/ja not_active Expired - Fee Related
- 1992-02-07 DE DE69232852T patent/DE69232852T2/de not_active Expired - Fee Related
- 1992-02-07 DK DK92907467T patent/DK0572549T3/da active
- 1992-02-07 AT AT92907467T patent/ATE227991T1/de not_active IP Right Cessation
- 1992-02-07 AU AU15319/92A patent/AU1531992A/en not_active Abandoned
- 1992-02-07 ES ES92907467T patent/ES2187500T3/es not_active Expired - Lifetime
- 1992-02-21 PT PT100155A patent/PT100155B/pt not_active IP Right Cessation
- 1992-02-21 MX MX9200755A patent/MX9200755A/es unknown
-
1995
- 1995-12-14 AU AU40427/95A patent/AU699436B2/en not_active Ceased
-
1996
- 1996-07-16 US US08/699,046 patent/US5756512A/en not_active Expired - Fee Related
-
1998
- 1998-12-15 HK HK98113537A patent/HK1012267A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU699436B2 (en) | 1998-12-03 |
| DE69232852T2 (de) | 2003-09-04 |
| DE69232852D1 (de) | 2003-01-02 |
| JP2738979B2 (ja) | 1998-04-08 |
| JPH06505741A (ja) | 1994-06-30 |
| AU4042795A (en) | 1996-02-22 |
| US5756512A (en) | 1998-05-26 |
| CA2103707C (en) | 2003-12-09 |
| WO1992014471A1 (en) | 1992-09-03 |
| PT100155A (pt) | 1993-05-31 |
| PT100155B (pt) | 1999-09-30 |
| EP0572549A1 (en) | 1993-12-08 |
| CA2103707A1 (en) | 1992-08-22 |
| DK0572549T3 (da) | 2003-01-06 |
| HK1012267A1 (en) | 1999-07-30 |
| EP0572549B1 (en) | 2002-11-20 |
| ES2187500T3 (es) | 2003-06-16 |
| ATE227991T1 (de) | 2002-12-15 |
| EP0572549A4 (es) | 1994-01-12 |
| KR930702984A (ko) | 1993-11-29 |
| AU1531992A (en) | 1992-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
| ATE105482T1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
| IT8522574A0 (it) | Composizione farmaceutica eprocedimento per trattare il corpo umano con essa. | |
| ATE282425T1 (de) | Verfahren zur behandlung von endothelialen verletzungen | |
| KR950700749A (ko) | 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent) | |
| MX9200755A (es) | Tratamiento de carcinoma pulmonar de celulas no pequeñas. | |
| IS4847A (is) | Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni | |
| EP0149579A3 (en) | Use of saccharomyces yeasts for preventing or treating pseudo-membranous colitis | |
| HK1006947A1 (en) | Treatment of liver cancer | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| CA2103708A1 (en) | Treatment of ovarian cancer | |
| AU562828B2 (en) | Morphine-vitamin b12 analgesic treatment | |
| NO984196L (no) | FremgangsmÕte for behandling av stoffmisbruk | |
| ZA9610073B (en) | Method of using beta-interferons to treat restenosis | |
| NO984198D0 (no) | Fremgangsmåte for behandling av aggresjon | |
| FI913531A0 (fi) | Anvaendning av 1,2-bensopyronderivater till behandling av maligna tumoerer hos maenniskan. | |
| DE69427468D1 (de) | Neue sulfatierte lyso-gangliosidederivate | |
| MX9706404A (es) | Metodo para tratar deplecion de adenosina. | |
| UA30787A (uk) | Спосіб лікування хронічного персистуючого гепатиту | |
| MX9405923A (es) | Mejoras en proceso para humectar y suavizar la piel. |